Norovirus vaccine (mRNA-1403)
Phase 3 interim analysis did not meet early-success criteria; the trial continues with an extra cohort.
What it is
mRNA-1403 is Moderna's vaccine candidate against norovirus, the common cause of stomach bugs and outbreaks. The Phase 3 study is still blinded. At its interim analysis, the data did not meet the criteria for early success, so Moderna plans to enroll an additional cohort.↗ source
Why it matters to the stock. A norovirus vaccine would open a new indication for the company, but the interim result pushes back any filing and makes the program a longer-dated bet.
News
Moderna Q2 2026 revenue rises to $145 million; 2026 guidance kept, R&D outlook cut
Moderna reported Q2 2026 total revenue of $145 million, up from $142 million a year earlier, while net product sales fell to $94 million from $114 million.
Earnings